Horizon Therapeutics Usa, Inc.
Deerfield, IL
- UEI
- SK1UK7S74GB3
- CAGE
- 6TDL9
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1 Horizon Way, Deerfield, IL 60015, USA
- Website
- amgen.com
- Founded
- 1980
- Employees
- 10K-50K
- Estimated annual revenue
- $10B+
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $228,331 |
| FY2024 | $390,136 |
| FY2023 | $1,948,088 |
Contract vehicles
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Krystexxa 8MG | Veterans Integrated Service Network 5 (VHA) | $76,897 | |
| Krystexxa 8MG | Veterans Integrated Service Network 5 (VHA) | $76,897 | |
| Krystexxa 8MG | Veterans Integrated Service Network 5 (VHA) | $37,269 | |
| Krystexxa 8MG | Veterans Integrated Service Network 5 (VHA) | $37,269 | |
| Krystexxa 8MG | Veterans Integrated Service Network 5 (VHA) | $55,903 |
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Ascendis Pharma, Inc. | — | 325412 Pharmaceutical Preparation Manufacturing |
| Acer Therapeutics Inc. | Boston, MA | 456110 Pharmacies and Drug Retailers |
| Vifor (International) AG | St. Gallen, SG | 325412 Pharmaceutical Preparation Manufacturing |
| Corcept Therapeutics Incorporated | Redwood City, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Incyte Corporation | Wilmington, DE | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Horizon Therapeutics USA Inc. is a global biotechnology company specializing in developing and commercializing medicines for rare, autoimmune, and severe inflammatory diseases. Registered in SAM.gov since November 2012, the company provides specialty pharmaceutical products to federal agencies, with a primary focus on delivering orphan drugs and targeted treatments through federal contract vehicles. The company is a for-profit organization headquartered in Deerfield, Illinois, with key facilities in locations such as La Vergne, Tennessee and Lake Forest, Illinois.
The company's federal contract awards predominantly involve delivering a specific medication called KRYSTEXXA (pegloticase), an 8mg pharmaceutical used to treat chronic gout, primarily to the Department of Veterans Affairs (VA) Veterans Health Administration. These delivery orders are consistently placed against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), with no set-aside designations. The contracts are typically firm fixed-price delivery orders ranging from approximately $14,000 to $467,000, servicing various Veterans Integrated Service Networks (VISNs), including VISN 2, 5, 12, 19, 20, 22, and 23. Beyond KRYSTEXXA, Horizon has also supplied other specialized medications like Ravicti, Buphenyl, Procysbi, and Actimmune to support VA healthcare services.
Horizon Therapeutics has a significant Indefinite Delivery Vehicle (IDV) in the form of a $31,375,000 single-award Blanket Purchase Agreement (BPA) with the VA's National Acquisition Center, effective from September 2024 through September 2025. This BPA is established against the GSA Schedule for Pharmaceuticals and Drugs and covers the procurement of multiple specialty medications including Ravicti, Buphenyl, Krystexxa, Procysbi, and Uplizna. The IDV allows VA medical centers and VISNs to efficiently place firm fixed-price orders for Horizon's portfolio of treatments for rare, autoimmune, and severe inflammatory diseases. This BPA complements Horizon's existing $25 million GSA Schedule contract, further establishing the company as a prime contractor supplying critical specialty pharmaceuticals to the VA healthcare system.
Quick answers
Is Horizon Therapeutics Usa, Inc. registered in SAM.gov?
Horizon Therapeutics Usa, Inc.'s SAM.gov registration expired on April 10, 2026.
What is Horizon Therapeutics Usa, Inc.'s CAGE code?
Horizon Therapeutics Usa, Inc.'s CAGE code is 6TDL9, and its Unique Entity ID (UEI) is SK1UK7S74GB3.
Which contract vehicles does Horizon Therapeutics Usa, Inc. hold?
Horizon Therapeutics Usa, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Horizon Therapeutics Usa, Inc. received in federal contracts?
Federal contracts obligated $228,331 to Horizon Therapeutics Usa, Inc. in fiscal year 2025 and $2,566,555 in fiscal years 2023 through 2027.
What is Horizon Therapeutics Usa, Inc.'s most recent federal award?
Horizon Therapeutics Usa, Inc.'s most recent federal contract award is Krystexxa 8MG (36C24525N0427), from Veterans Integrated Service Network 5 (VHA), on February 28, 2025.
On GovTribe
See Horizon Therapeutics Usa, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors